You are not logged in. Press here to login.


List volumes - List articles in this issue

Cost-effectiveness of botulinum toxin type a in the treatment of post-stroke spasticity

doi: 10.1080/16501970510027312

Open access


OBJECTIVE: Treatment strategies for post-stroke spasticity include oral anti-spastic drugs, surgery, physiotherapy and botulinum toxin type A injection. The objective of this study was to compare the cost-effectiveness and outcomes of oral therapy vs. botulinum toxin type A treatment strategies in patients with flexed wrist/clenched fist spasticity.METHODS: Treatment outcome and resource use data were collected from an expert panel experienced in the treatment of post-stroke spasticity. A decision tree model was developed to analyse the data.RESULTS: Thirty-five percent of patients receiving oral therapy showed an improvement in pre-treatment functional targets which would warrant continuation of therapy, compared with 73% and 68% of patients treated with botulinum toxin type A first- and second-line therapy, respectively. Botulinum toxin type A treatment was also more cost-effective than oral therapy with the “cost-per-successfully-treated month” being £942, £1387 and £1697 for botulinum toxin type A first-line, botulinum toxin type A second-line and oral therapy, respectively.CONCLUSION: In conclusion, botulinum toxin type A is a cost-effective treatment for post-stroke spasticity.


Anthony Ward A1, Graeme Roberts A2, Juliet Warner A3, Samantha Gillard A3
A1 North Staffordshire Rehabilitation Unit, The Hayward, Stoke-on-Trent, Staffordshire
A2 Allergan Ltd, Buckinghamshire
A3 Abacus International, Bicester, Oxfordshire, UK

Related articles

There are no related articles.





There is no supplementary for this article.

Related articles

Click here to show related articles

Print information

Volume 37, Issue 4

DOI: 10.1080/16501970510027312

Pages: 252-257

View at PubMed